13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001643354
Total reported value
$20.9M
$20.9M
27 檔
169.9%
During the Q2 2024 filing period, Lion Point Capital, LP (CIK: 0001643354) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $20.9M across 27 reported positions.
During Q2 2024, Lion Point Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 30.51% | — | -66.67% | |
| 2 | ARDX | Ardelyx Inc | Stock-Other | 11.57% | -1.47% | -18.15% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 8.59% | — | — | |
| 4 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 8.45% | — | — | |
| 5 | MIST | Milestone Pharmaceuticals In | Stock-Other | 5.63% | -0.57% | +1.74% | |
| 6 | GERN | Geron CORP | Stock-Other | 4.87% | -1.61% | +5.00% | |
| 7 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 4.51% | — | -0.20% | |
| 8 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 3.56% | — | — | |
| 9 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.80% | — | — | |
| 10 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.43% | -1.27% | — | |
| 11 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.26% | -0.44% | — | |
| 12 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.11% | — | — | |
| 13 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.10% | — | +11.33% | |
| 14 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 1.89% | +1.65% | — | |
| 15 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.69% | -0.34% | +31.67% | |
| 16 | ✓ | Enphys Acquisition CORP | Stock-Other | 1.56% | — | — | |
| 17 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.32% | -1.50% | — | |
| 18 | ✓ | Stock-Other | 1.22% | — | -20.04% | ||
| 19 | 0LS | Burgerfi International Inc | Stock-Other | 1.02% | — | — | |
| 20 | RGNX | Regenxbio Inc | Stock-Other | 0.77% | +0.19% | +11.54% | |
| 21 | MCRB1EUR | Seres Therapeutics Inc | Stock-Other | 0.45% | — | — | |
| 22 | 4NX1 | Lumos Pharma Inc | Stock-Other | 0.38% | — | — | |
| 23 | MSFT | Microsoft CORP | Stock-Tech | 0.08% | — | — | |
| 24 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.07% | — | — | |
| 25 | ✓ | Burgerfi International Inc | Stock-Other | 0.05% | — | — | |
| 26 | BATL | Battalion Oil CORP | Stock-Other | 0.05% | — | -62.75% | |
| 27 | GOOG | Alphabet Inc-cl C | Stock-Comm Services | 0.03% | — | — |
According to official SEC Form 13F filings, Lion Point Capital, LP reported a total U.S. public equity portfolio value of $20.9M across 27 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including IWM, ARDX, INSM) accounted for 169.9% of total reported equity market value during Q2 2024.
During Q2 2024, Lion Point Capital, LP's top holdings by market value included IWM (30.5%)、ARDX (11.6%)、INSM (8.6%). The largest single position, IWM, represented 30.5% of total portfolio value.
In Q2 2024, Lion Point Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.